Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of the 2023 Autumn XBB.1.5 COVID-19 Booster During Summer 2024 in the EU/EEA: A VEBIS Electronic Health Record Network Study.
Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Fabiani M, Castilla J, Martínez-Baz I, Machado A, Soares P, Ljung R, Pihlström N, Kissling E, Nardone A, Monge S, Bacci S, Nunes B; VEBIS‐EHR working group. Humphreys J, et al. Among authors: pihlstrom n. Influenza Other Respir Viruses. 2025 Dec;19(12):e70198. doi: 10.1111/irv.70198. Influenza Other Respir Viruses. 2025. PMID: 41312816 Free PMC article.
SARS-CoV-2 vaccination and myositis in Norway and Sweden.
Ljung R, Pihlström N, Dahl J, Tapia G, Sundström A, Nurminen ML, Lundberg IE, Karlstad Ø, Holmqvist M, Feltelius N. Ljung R, et al. Among authors: pihlstrom n. Rheumatology (Oxford). 2026 Feb 4;65(2):keaf609. doi: 10.1093/rheumatology/keaf609. Rheumatology (Oxford). 2026. PMID: 41273774
Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data.
Faksova K, Thiesson EM, Pihlström N, Baum U, Biering-Sørensen T, Poukka E, Leino T, Ljung R, Hviid A. Faksova K, et al. Among authors: pihlstrom n. Lancet Reg Health Eur. 2025 Nov 3;60:101518. doi: 10.1016/j.lanepe.2025.101518. eCollection 2026 Jan. Lancet Reg Health Eur. 2025. PMID: 41255775 Free PMC article.
Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time: Report from the Swedish Medical Products Agency and the Public Health Agency of Sweden.
Zethelius B, Rubin J, Pihlström N, Liminga UW, Back H, Aronsson B, Tegnell A, Marking U, Ludvigsson JF, Andersson S, Ljung R. Zethelius B, et al. Among authors: pihlstrom n. Ups J Med Sci. 2025 Oct 16;69. doi: 10.48101/ujms.v130.12937. eCollection 2025. Ups J Med Sci. 2025. PMID: 41189699 Free PMC article. Review.
Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
Humphreys J, Blake A, Nicolay N, Braeye T, Van Evercooren I, Hansen CH, Moustsen-Helms IR, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, Machado A, Brito A, Ljung R, Pihlstrom N, Mansiaux Y, Monge S, Bacci S, Nunes B; VEBIS-EHR working group. Humphreys J, et al. Among authors: pihlstrom n. Vaccine. 2025 Oct 3;64:127752. doi: 10.1016/j.vaccine.2025.127752. Epub 2025 Sep 19. Vaccine. 2025. PMID: 40974735 Free PMC article.
FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells.
Kao KS, Pihlstrom NL, Niejadlik EG, Cantaert T, Ahmed R, Ravetch JV, Bournazos S. Kao KS, et al. Among authors: pihlstrom nl. Proc Natl Acad Sci U S A. 2025 Jul 8;122(27):e2509016122. doi: 10.1073/pnas.2509016122. Epub 2025 Jul 1. Proc Natl Acad Sci U S A. 2025. PMID: 40591599 Free PMC article.
27 results